Market Place
Sourcing Support
Almirall Reports Q3 2024 Results Driven by Dermatology Portfolio
11 Nov 2024 //
BUSINESSWIRE
Almirall focuses on role of friends and family for psoriasis day
30 Oct 2024 //
FIERCE PHARMA
Centrient opens Innovation Lab in Barcelona`s Product Development
21 Oct 2024 //
PRESS RELEASE
Almirall Completes Efinaconazole Approval Procedure In Europe
15 Oct 2024 //
BUSINESSWIRE
New Data Almirall`s Ebglyss Shows 3-Year Atopic Dermatitis
25 Sep 2024 //
BUSINESSWIRE
Almirall To Present New Psoriasis Atopic Dermatitis Data
23 Sep 2024 //
BUSINESSWIRE
Almirall focuses on mental burden of skin disease for eczema day
16 Sep 2024 //
FIERCE PHARMA
Almirall Reports 6.7% Net Sales Growth In H1 2024 Led By Dermatology
22 Jul 2024 //
BUSINESSWIRE
NICE Recommends Ebglyss For Atopic Dermatitis In NHS England
10 Jul 2024 //
BUSINESSWIRE
Almirall Launches Act4Impact Sustainability Strategy With 2030 Targets
02 Jul 2024 //
BUSINESSWIRE
Almirall`s Ilumetri Restores Patient Wellbeing in Severe Plaque Psoriasis
28 Jun 2024 //
BUSINESSWIRE
FDA Approves Almirall`s Klisyri For Expanded Actinic Keratosis Treatment
10 Jun 2024 //
BUSINESSWIRE
Almirall’s Klisyri approved to treat larger actinic keratosis areas
10 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Almirall `Stay Vigilant` Actinic Keratosis Awareness Campaign Launched
30 May 2024 //
FIERCE PHARMA
Almirall Q1 2024: 6.6% Growth, EU Derma +18%
13 May 2024 //
BUSINESSWIRE
Novo Licenses to Almirall Potential First-in-Class Antibody Candidate
20 Feb 2024 //
BIOSPACE
Almirall continues its progress to leadership in Medical Dermatology
19 Feb 2024 //
BUSINESSWIRE
Almirall Initiates First Phase I Clinical Study of ALM223
21 Dec 2023 //
BUSINESSWIRE
Almirall partners with etherna
12 Dec 2023 //
ENDPTS
Almirall`s Ebglyss (Lebrikizumab) Receives Approval in Europe
24 Nov 2023 //
EMA
Almirall Receives European Commission Approval of EBGLYSS
17 Nov 2023 //
BUSINESSWIRE
Almirall and Absci announce AI drug discovery partnership
14 Nov 2023 //
BUSINESSWIRE
Almirall’s Nine-month 2023 Results:
09 Nov 2023 //
BUSINESSWIRE
Almirall: 80% of patients with atopic dermatitis maintained clear skin with lebrikizumab
20 Oct 2023 //
BUSINESSWIRE
Almirall`s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe AD
13 Oct 2023 //
BUSINESSWIRE
Almirall signs $210M deal with EpimAb to develop bispecifics
12 Oct 2023 //
FIERCE BIOTECH
Almirall`s Ilumetri® (tildrakizumab) Significantly Improves Wellbeing
11 Oct 2023 //
BUSINESSWIRE
Centrient Pharmaceuticals joins Almirall’s growing innovation hub in Barcelona
10 Oct 2023 //
PRESS RELEASE
Almirall Upgrades Werum PAS-X MES
19 Sep 2023 //
CONTRACT PHARMA
EBGLYSS Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
15 Sep 2023 //
BUSINESSWIRE
Almirall Achieves Net Sales Growth of 7% to €466.1MM
24 Jul 2023 //
BUSINESSWIRE
Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis
07 Jul 2023 //
BUSINESSWIRE
Almirall makes dramatic mini-series to show life with psoriasis
27 Jun 2023 //
FIERCE PHARMA
Almirall launches Nina, the first series to highlight the major impact
20 Jun 2023 //
BUSINESSWIRE
Almirall announces the pricing of €200mm non pre-emptive share capital increase
13 Jun 2023 //
BUSINESSWIRE
Almirall Announces the Launch of a €200mm Non Pre-Emptive Share Capital Increase
12 Jun 2023 //
BUSINESSWIRE
Almirall finds 85% of patients are unaware of Klisyri indication
05 Jun 2023 //
FIERCE PHARMA
Almirall: Up to 73% of Atopic Der Patients Taking Lebrikizumab Had Improved
01 May 2023 //
BUSINESSWIRE
Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study
12 Apr 2023 //
BUSINESSWIRE
Almirall: (NEJM) and the (BJD) Publish Ph3 Data Evaluating lebrikizumab Efficacy
31 Mar 2023 //
BUSINESSWIRE
ZeClinics Moves Headquarters to Almirall R&D Centre
27 Feb 2023 //
CONTRACT PHARMA
Spain`s Almirall expects core earnings to fall in 2023
20 Feb 2023 //
REUTERS
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
BUSINESSWIRE
Almirall signs on with clinical trial project to collect data
29 Nov 2022 //
FIERCEBIOTECH
Almirall joins FACILITATE, a patient-driven IMI project
28 Nov 2022 //
BUSINESSWIRE
Almirall to take part in FACILITATE project to enable trial data usage
28 Nov 2022 //
CLINICALTRIALSARENA
Almirall sheds light on the mental effects of psoriasis
23 Nov 2022 //
FIERCEPHARMA
Almirall’s Nine-month 2022 Results
10 Nov 2022 //
BUSINESSWIRE
Spain`s Almirall Q3 core earnings fall 13%; keeps outlook
10 Nov 2022 //
REUTERS
Almirall PROSES shows acne treatment decreases burden of impact on sufferers
21 Oct 2022 //
BUSINESSWIRE
Enforcement Report - Week of October 5, 2022
05 Oct 2022 //
FDA
Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
30 Sep 2022 //
PRESS RELEASE
Almirall`s Klisyri receives strong recommendation in AAD AK guideline update
18 Aug 2022 //
PRNEWSWIRE
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
25 Jul 2022 //
PRNEWSWIRE
Almirall launches new call to find innovative therapies for skin diseases
21 Jul 2022 //
PHARMIWEB
Almirall-backed psoriasis support app Claro launches in Europe
14 Jun 2022 //
PHARMAPHORUM
Happify Health and Almirall Go Live with Digital Solution
13 Jun 2022 //
BUSINESSWIRE
Almirall: `Listen to what your marks whisper to you`
26 May 2022 //
FIERCEPHARMA
Almirall rolls out sales rep AI system, cutting pre-call prep
26 May 2022 //
ENDPTS
Dermatology Pact Latest to Showcase Broad Potential of Evotec`s Platform
19 May 2022 //
BIOSPACE
